Hotchkiss Insurance  ·  Employee Benefits Intelligence

The Benefits Brief

For CFOs and HR leaders who don't have time for filler. A monthly read on the regulatory shifts, market moves, and money on the table.

Inside This Issue

Story 01 · Excepted Fertility Benefits

The Federal Fertility Benefits Rule Has a 13-Day Comment Window.

On May 13, the Departments of Labor, HHS, and Treasury proposed creating a new category of "limited excepted benefits" for fertility coverage — a standalone benefit, capped at $120,000 lifetime, that operates outside your major medical plan. Comments close July 13. The rule takes effect for plan years beginning January 1, 2027.

Until now, employers wanting to offer fertility coverage outside their major medical plan faced an administrative thicket: ERISA, HIPAA portability, ACA market reforms, the No Surprises Act, and several state laws each had to be reconciled. The result, in practice, was that most employers either rolled fertility into their major medical plan or skipped it entirely. The proposed rule cuts that knot. Fertility becomes a standalone benefit, like dental or vision — exempt from the major medical compliance overlay.

The structural design matters. To qualify as an excepted benefit, the program must satisfy four conditions: (1) substantially all benefits must be for diagnosis, mitigation, or treatment of infertility or related reproductive health conditions, delivered by licensed medical professionals; (2) lifetime cap of $120,000 combined for participant and beneficiaries; (3) separation from major medical — the employer must still offer a traditional plan, but employees do not need to enroll in it to access the fertility benefit; and (4) a specific participant notice with summary of benefits, network access, and claims procedure.

There is one open problem the proposed rule does not solve, and it matters specifically for employers with HDHP/HSA enrollees. The IRS has not addressed whether enrollment in an excepted fertility benefit disqualifies HSA contributions. The agencies acknowledged the issue and left it for separate guidance. For a CFO whose workforce includes HSA participants, this is a real uncertainty: if your employee is enrolled in the major medical HDHP and also in a fertility benefit with first-dollar coverage, the existing HSA framework would suggest disqualification — and nonqualified HSA contributions face income tax plus a 20% penalty.

Story 02 · No Surprises Act IDR

No Surprises Act IDR Fees Just Dropped 85%. Expect a Wave of Disputes On Claims You'd Never Bother Defending.

On May 28, the Departments finalized the Federal IDR Operations rule. The administrative fee dropped from $115 to $15 per party — effective for disputes initiated on or after June 11. The economics of provider-initiated disputes just changed.

The IDR process is how providers and self-funded plans resolve disagreements over out-of-network payment rates under the No Surprises Act. Since launch in April 2022, the system has been overwhelmed — 5.1 million disputes against a projected first-year load in the tens of thousands. The volume created administrative backlog, but it also created an unintended filter: at $115 per party, small-dollar disputes simply weren't worth filing. That filter is gone.

There is a second change in this rule that most CFOs will miss but that matters for self-funded plan governance. Plans must now register in the Federal IDR portal. Each registrant receives an IDR registration number that providers use to identify the correct plan party. The registry requirements become applicable 90 business days after the Departments issue guidance announcing the supporting functionality. Practically, this means by Q4 2026, your TPA — or your in-house benefits team if you administer claims directly — needs to have completed federal registration. The compliance lift is small; the consequence of missing it is that providers cannot correctly route disputes to your plan.

The rule also requires payors to use standardized claim adjustment reason codes (CARCs) and remittance advice remark codes (RARCs) on every out-of-network remittance — even claims not subject to NSA. The Departments declined to add penalties for noncompliance but will monitor. This is a TPA operational lift, not an employer lift directly — but if your TPA can't code remittances correctly, you'll see ineligible disputes get accepted into IDR that should have been screened out.

Story 03 · Oncology Cost Containment

Cancer Is the $1 Trillion Plan Design Question. The Real Lever Is Site-of-Care.

Cancer is the top employer health cost driver for the fourth year running. The headline statistic everyone repeats — 95% of new anticancer therapies launch above $100,000 per year — frames cancer as a drug pricing problem. It isn't. It's a site-of-care problem. The same infused drug costs 86% more at a hospital outpatient department than at a physician office.

The Employee Benefits Research Institute studied infused cancer drug prices and found hospital outpatient departments charged an average 86.2% more per unit than physician offices for the top 37 infused cancer drugs. For specific drugs, the gap was wider — 128% for nivolumab, 428% for fluorouracil. Same drug. Same dose. Same patient outcome. The line-item difference is purely site-of-care. That isn't a clinical question, it's a routing question.

There are two practical levers a self-funded employer can pull. The first is Centers of Excellence: contracted networks of high-volume cancer treatment facilities that deliver standardized, evidence-based care at negotiated rates. About half of large employers offer a cancer COE in 2026; another 23% are considering one by 2028. The second is specialty pharmacy site-of-care redirection: steering infused cancer drugs out of hospital outpatient settings and into physician offices, ambulatory infusion centers, or home infusion where clinically appropriate. The savings are not theoretical — case studies show 25–30% reductions in per-episode cancer costs.

The integration matters more than either lever individually. A COE without a site-of-care redirect strategy captures the diagnosis and treatment-planning value but leaves the infused drug cost arbitrage on the table. A specialty pharmacy carve-out without a COE captures the drug-routing value but misses the upstream treatment selection. The employers running 8–12% under trend on oncology spend are doing both.

Following Up

What changed since June.

Three open loops from last issue. One is progressing as forecast. One has new data. One is quieter than expected.

On My Radar

Three stories worth tracking before they become your problem.

Not yet ready for full coverage. Each one will shape someone's 2027 renewal — and the employers who see them coming get the cheaper outcome.

Get In Touch

Questions about what you just read? Let's talk.

No sales pitch. No pressure. Just an honest conversation about where your benefits strategy stands — and where it could go.

"The system wasn't built for employers. I help you build one that was."